Account
Inquiry
Tirzepatide 10mg is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist currently under development for type 2 diabetes treatment and weight management research.
This white powder formulation contains 99.9% pure tirzepatide (LY3298176) with molecular formula C225H348N48O68. Clinical studies demonstrate tirzepatide 10mg shows superior efficacy in glucose control and weight reduction compared to selective GLP-1 receptor agonists.
The mechanism of action involves tirzepatide 10mg binding to both GIP and GLP-1 receptors, with greater affinity for GIP receptors. This dual agonist behavior produces enhanced glycemic control effects. The molecular structure features PEG modification on the lys side chain, improving water solubility.
Research indicates tirzepatide 10mg promotes significant weight loss in clinical trials. The SURMOUNT-1 study reported average weight reduction of 19.5% with the 10mg dose after 72 weeks. This makes tirzepatide 10mg a promising candidate for obesity-related research.
As a weekly administered peptide, tirzepatide 10mg combines the benefits of two incretin hormones into a single molecule, representing an innovative approach to metabolic disorder research. The compound has received FDA Fast Track designation for obesity treatment studies.
For research use only. Not for human consumption. Proper storage conditions are essential to maintain peptide stability - keep in a cool, dry, dark environment and avoid repeated freeze-thaw cycles.
